Endocrine Therapy: 36 Real Stories

36 stories match endocrine therapy. 27 of them mention surgery.

Cancer Stories

Liz, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Liz's Survivor Story

Patient Info: Liz O’Riordan, Female, 40s

Technically cancer-free after 2 local recurrences, with no metastatic disease stated, while continuing lifelong monthly injection treatment to reduce the risk of metastatic disease and living with scanxiety.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Breast Cancer in a Woman Carrying Both BRCA1 and BRCA2 Mutations

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative, BRCA1 pathogenic variant, BRCA2 pathogenic variant

Remained free of recurrence 17 months after treatment.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Returning About 20 Years After Initial Treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones

About 20 years after her original breast-cancer treatment and sustained remission, bone biopsy confirmed metastatic recurrence; she became too unwell for planned cancer therapy and chose supportive care.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage III Breast Cancer Complicated by a Large Liver Abscess

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER-positive, HER2-negative

Continuing adjuvant anastrozole and oncology follow-up after mastectomy for Stage III breast cancer.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Male Breast Cancer Responding to Abemaciclib and Letrozole

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: soft tissue, distant lymph nodes, bone

The tumor and metastatic soft-tissue and lymph-node disease shrank markedly, with no progression on July 2024 imaging and good clinical condition in September 2024.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Breast CancerBreast Cancer

Vision problems led to a breast cancer diagnosis (cancer-associated retinopathy)

Patient Info: Anonymized, Female

Biomarkers: Anti-recoverin and anti-alpha-enolase antibodies associated with cancer-associated retinopathy; tumor biomarkers not reported

Six years after her initial visual symptoms, vision remained stable and she remained cancer-free on surveillance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Breast CancerBreast Cancer

A Breast Cancer Survivor Later Diagnosed With a Separate Metastatic Cancer Affecting Both Retinas

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative

Her last breast-cancer follow-up showed no evidence of disease after 5 years of endocrine therapy. She later developed a separate widely metastatic cancer favored to be gastrointestinal or pancreaticobiliary in origin and died after choosing hospice.

PubMed Central
OutcomeIn Memory